Nest Genomics
Nest Genomics, the trading name of Nest Health Inc. and a Y Combinator company, sells a genomic care platform that runs inside the electronic health record. Branded the Nest Genetics Copilot, it identifies patients who may need genetic testing, collects personal and family history, handles education and consent, routes orders to the laboratory of the clinic's choice, stores results as structured data, and generates care plans that follow current guidelines as results and guidelines change. Partner laboratories include Ambry Genetics, Natera, Invitae, MyOme, Myriad Genetics and GeneType.
Nest describes itself as AI native and says its models are trained on genomic datasets to identify patterns and suggest workflows, with human in the loop verification and recommendations aligned to guidelines. An earlier GenomeWeb account, from the time of its seed round, described the care plans as rule based clinical decision support built on ACMG and specialty society guidelines. Nest says its analysis is never used for automatic decisions, only to support clinicians.
It works with Epic, athenahealth, where it has been listed in the Marketplace since October 2024, eClinicalWorks and AdvancedMD, and names Rady Children's Hospital San Diego, Baptist Health, Geisinger, Dana-Farber Cancer Institute, Mount Sinai and Ms. Medicine among its users. Nest acts as a business associate of its health system customers, hosts on AWS and displays SOC 2 Type II certification. No price is published.
Capability Axes
An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read
A learned layer is claimed on a workflow and guideline product whose value stands without it. Most of what Nest delivers is workflow inside the record: risk questionnaires, education and consent, lab agnostic ordering, structured results storage and care plans that follow published guidelines. Nest's AI philosophy page says its models are trained on genomic datasets to identify patterns and suggest workflows that generic language models miss, and its home page describes AI powered algorithms that surface patients for testing.
Neither page says which function a trained model performs, and an earlier GenomeWeb account described the care plans as rule based. Read together, a learned component is claimed for patient identification and workflow suggestion, beside a core that works on rules.
Human oversight is asserted without a described mechanism. Nest's privacy policy says its analysis alone is never used for automatic decision making and only augments customers' human decisions, and the AI philosophy page refers to human in the loop verification and development with genetic counselors and key opinion leaders. Clinicians order tests and act on care plans.
What is not published is how a flagged patient or a suggested workflow is reviewed, who can override a care plan, or what happens when a suggestion conflicts with the clinician's judgment.
The approach is described in general terms with nothing identified. Nest's AI philosophy page says its models are trained on genomic datasets to identify patterns and suggest workflows, and that care plans follow guidelines with custom workflows for complex results. No model, model type, training data source, supplier or version practice is named.
The architecture is described and no model provider is named. Nest names AWS as its host and Google Analytics, PostHog and a self hosted OpenReplay as analytics tools in its privacy policy. Its AI philosophy page contrasts its models with generic language models without saying whether any outside model service is used, and no subprocessor list for patient data is published.
A named customer with vendor reported figures and no method. Nest's October 2024 athenahealth announcement reports that at Ms. Medicine, a primary care network for women, 80 percent of patients completed the risk assessment, 52 percent were identified as high risk and 38 percent met genetic testing criteria, and that Nest was in use at more than 10 health systems and 50 clinics. Rady Children's Hospital San Diego, Baptist Health, Geisinger, Dana-Farber Cancer Institute and Mount Sinai are named as users.
No denominator, period, comparison or downstream result, such as tests completed or cancers found, is given, and no study of the platform is published. Scale of use is not evidence of benefit.
General assurances, with the questions the models raise left open. Nest's privacy policy says provider customers control patient data, that records are kept at least six months after service and account data until closure, and that its analysis supports rather than replaces human decisions. Its security page says data is encrypted in transit and at rest on HIPAA eligible AWS services.
Nothing published says whether customer patient data trains the models the AI philosophy page describes, which de identification method applies, or what reaches any outside model service. Safety engineering for the models, meaning guardrails and how an error would be detected and handled, is not published.
Business associate status is stated and supported, and the agreement is not published. Nest Health Inc.'s privacy policy, updated August 2026, covers its website, mobile app and web platform for genetic testing decision support, says Nest acts as a business associate to healthcare providers and processes patient information under the provider's business associate agreement or Nest's standard one, and says patient information is governed by the provider's privacy policies and HIPAA. Its security page states HIPAA compliance.
Nest's standard business associate agreement is referred to and not published, and the policy does not say whether it binds subcontractors.
A recognized certification is named without the artifact. Nest displays SOC 2 Type II certification and describes encryption, access controls, monitoring, secure development and vulnerability testing on its security page, with a security contact for questions and vulnerability reports. The SOC 2 report, its date and its scope are not published.
No device claim is made, and no regulatory position is published. Nest's care plans follow published guidelines and are shown to clinicians, who act on them, so each recommendation has a basis a clinician can check; Nest says its analysis is never used for automatic decisions. It has not said how it classifies the patient identification and care plan features, for example under the clinical decision support provisions that exempt some software from device regulation.
A development process is described and no evaluation is published. Nest says its platform was developed with genetic counselors and key opinion leaders and that recommendations are guideline driven with human verification. No accuracy evaluation of the models, no results by ancestry, age or sex, and no change control for models or care plan content are published, which matters because family history based screening misses some groups more than others.
Clinician review is the mechanism, and nothing stands behind the output. Nest's suggestions and care plans reach clinicians, who decide, and Nest says its analysis is never used for automatic decisions, so a wrong suggestion can be caught before it affects care.
No error rate for patient identification, no warranty, indemnity or remediation commitment for care plan content, and no route for a patient affected by a missed or wrong recommendation is published.
Named record systems with ordering and results inside them, and a marketplace listing. Nest names Epic, athenahealth, eClinicalWorks and AdvancedMD, with Redox among its integration routes, and announced in October 2024 that the Nest Genetics Copilot is available through athenahealth's Marketplace program, with Ms. Medicine named as a customer. It describes ordering from any laboratory and structured ingestion of results that stay current in the record.
No integration documentation or listing detail shows which data is written back into each record system, and no Epic site is named as live on Nest's pages.
A single hosted service with location implied. Nest's security page says the platform is built on HIPAA eligible AWS services with encryption in transit and at rest, and its privacy policy limits the products to users in the United States and Australia. No AWS region, data location commitment for either country, or tenant isolation is described.
No price is published and how the platform is sold can be established. Nest sells to health systems and clinics, runs inside their record systems including through the athenahealth Marketplace, and routes orders to any partner laboratory, so the buyer is the provider organization rather than a laboratory. No subscription fee, per patient or per order charge, or implementation fee is published.
Coverage is stated with nothing validating it yet. Nest serves health systems, primary care and women's health networks, cancer centers and a children's hospital, across hereditary cancer, cardiovascular genetics and secondary findings from broader sequencing, and is offered in the United States and Australia. No evaluation is published for any setting or specialty.
Alternatives to Nest Genomics
Other products that do the same kind of work as Nest Genomics, and what each one does.
Ambry Genetics is a genetic testing laboratory in Aliso Viejo, California, founded in 1999 and owned since 2025 by Tempus AI.
Tempus (NASDAQ: TEM) is a Chicago precision medicine company whose core business is molecular laboratory testing, alongside software for clinicians and data work with drug developers.
Avo is a clinician built decision support platform whose foundation is content rather than a model.
Navina, a New York company founded in 2018, sells a clinician copilot for value based primary care.
Invitae is a genetic testing brand owned by Labcorp, which acquired the business in 2024 after Invitae's bankruptcy. It keeps its own site and test menu and now presents itself as Invitae and Labcorp together, with some billing handled by Labcorp Genetics.
Genomics company in San Mateo, California, sequencing with its proprietary Exome+ assay in a CLIA certified, CAP accredited laboratory.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Not published
|
Platform sold to health systems and clinics, running inside their record systems and routing orders to any partner laboratory; no unit of charge published. | Business associate to provider customers under the provider's agreement or Nest's standard agreement, which is not published. | Not published. | Vendor Published |
Nest names its buyers, record systems (including the athenahealth Marketplace) and partner laboratories without a subscription fee, per patient or per order charge, or implementation fee. Whether laboratories pay any part of the cost is not stated.